{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:13:40Z","timestamp":1698732820505},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>Imiquimod 3.75% cream is a new formulation intended for daily self\u2010application. The objective of this study was to characterize serum imiquimod pharmacokinetics under maximal use conditions. Adults with \u22658 warts or total wart area \u2265100 mm<jats:sup>2<\/jats:sup> applied up to 1 packet of imiquimod 3.75% cream (250 mg cream, 9.375 mg imiquimod) once daily for 3 weeks. Blood was obtained prior to doses 1, 7, 14, and 21 and at selected time points after doses 1 and 21. Eighteen patients (13 men and 5 women) with a median wart count of 16 and total wart area of 60 mm<jats:sup>2<\/jats:sup> were enrolled. Day 21 mean (SD) serum C<jats:sub>max<\/jats:sub> was 0.49 (0.37) ng\/mL, AUC<jats:sub>0\u201324<\/jats:sub> 6.80 (3.59) ng\u00b7h\/mL, and t<jats:sub>1\/2<\/jats:sub> 24.1 (12.4) hours. Steady state was achieved by day 7 with \u223c2\u2010fold increase in C<jats:sub>max<\/jats:sub> and AUC after multiple dosing. Overall, C<jats:sub>max<\/jats:sub> was higher and t<jats:sub>max<\/jats:sub> shorter in women, with comparable AUC<jats:sub>0\u201324<\/jats:sub>. Imiquimod metabolites were sporadically quantifiable. No patients discontinued for adverse events; 1 interrupted dosing for an application site ulcer. Treatment\u2010related adverse events occurred in 16.7% of the patients. In conclusion, serum imiquimod concentrations were low after daily self\u2010application to external anogenital warts of up to 1 packet of imiquimod 3.75% cream for 21 days.<\/jats:p>","DOI":"10.1177\/0091270011407192","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T01:41:58Z","timestamp":1326159718000},"page":"828-836","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics of Daily Self\u2010Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts"],"prefix":"10.1002","volume":"52","author":[{"given":"Jason","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni758"},{"issue":"4","key":"e_1_2_5_3_2","first-page":"36","article-title":"Mechanism of action and other potential roles of an immune response modifier","volume":"79","author":"Gaspari AA","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.569"},{"key":"e_1_2_5_5_2","first-page":"5176","article-title":"Phase I trial of an oral immunomodulator and interferon inducer in cancer patients","volume":"53","author":"Witt PL","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_6_2","first-page":"467","article-title":"Beyond a decade of 5% imiquimod topical therapy","volume":"8","author":"Gaspari A","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_7_2","volume-title":"Aldara (imiquimod cream, 5%) [prescribing information]","year":"2009"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-004-0465-4"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.25"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200104000-00007"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/095646240101200105"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(01)00573-2"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","unstructured":"FerrisDG BakerD TyringS et al.Imiquimod 2.5% and 3.75% applied daily for up to 8 weeks to treat external genital warts. Presented at: HPV 2010;2010; Montreal Quebec Canada. Abstract P544.","DOI":"10.1016\/j.contraception.2010.04.129"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1041-8"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP38476"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.7.3.437"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1068-607X(98)00034-1"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011407192","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011407192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:27:01Z","timestamp":1698640021000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011407192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1177\/0091270011407192"],"URL":"https:\/\/doi.org\/10.1177\/0091270011407192","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}